PM
NVO

Penbrook Management’s Novo Nordisk NVO Stock Holding History

Penbrook Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.6M Sell
316,200
-200
-0.1% -$9.48K 8.8% 1
2025
Q4 		$16.1M Buy
316,400
+4,800
+2% +$245K 11.1% 1
2025
Q3 		$17.3M Sell
311,600
-311,200
-50% -$18.2M 12.07% 1
2025
Q2 		$43.1M Buy
622,800
+311,400
+100% +$21.2M 16.25% 1
2025
Q1 		$21.6M Sell
311,400
-1,000
-0.3% -$82.6K 16.34% 1
2024
Q4 		$26.9M Sell
312,400
-100
-0% -$10.8K 18.33% 1
2024
Q3 		$37.2M Sell
312,500
-100
-0% -$13.3K 24.19% 1
2024
Q2 		$44.6M Hold
312,600
– – 27.24% 1
2024
Q1 		$40.1M Sell
312,600
-600
-0.2% -$71.4K 24.88% 1
2023
Q4 		$32.4M Sell
313,200
-4,000
-1% -$396K 21.77% 1
2023
Q3 		$28.8M Hold
317,200
– – 21.14% 1
2023
Q2 		$25.7M Sell
317,200
-1,200
-0.4% -$98K 18.6% 1
2023
Q1 		$25.3M Sell
318,400
-1,800
-0.6% -$128K 19.41% 1
2022
Q4 		$21.7M Sell
320,200
-22,100
-6% -$1.3M 18.47% 1
2022
Q3 		$17.1M Sell
342,300
-1,000
-0.3% -$53.6K 14.68% 1
2022
Q2 		$19.1M Hold
343,300
– – 15.08% 1
2022
Q1 		$19.1M Hold
343,300
– – 12.37% 1
2021
Q4 		$19.2M Hold
343,300
– – 11.58% 1
2021
Q3 		$16.5M Sell
343,300
-600
-0.2% -$29K 10.24% 1
2021
Q2 		$14.4M Hold
343,900
– – 8.63% 1
2021
Q1 		$11.6M Buy
343,900
+200
+0.1% +$7.12K 8.34% 1
2020
Q4 		$12M Buy
343,700
+90,000
+35% +$3.11M 9.25% 1
2020
Q3 		$8.81M Buy
253,700
+1,000
+0.4% +$33.3K 7.63% 2
2020
Q2 		$8.27M Hold
252,700
– – 8.14% 2
2020
Q1 		$7.61M Sell
252,700
-1,000
-0.4% -$29.8K 9.74% 1
2019
Q4 		$7.34M Hold
253,700
– – 7.15% 1
2019
Q3 		$6.56M Sell
253,700
-400
-0.2% -$10.1K 7.12% 1
2019
Q2 		$6.49M Sell
254,100
-2,000
-0.8% -$49.4K 6.96% 1
2019
Q1 		$6.7M Hold
256,100
– – 6.96% 1
2018
Q4 		$5.9M Sell
256,100
-1,100
-0.4% -$24.4K 6.73% 1
2018
Q3 		$6.06M Hold
257,200
– – 5.81% 1
2018
Q2 		$5.93M Hold
257,200
– – 5.7% 1
2018
Q1 		$6.33M Sell
257,200
-1,000
-0.4% -$26.3K 6.33% 1
2017
Q4 		$6.93M Buy
+258,200
New +$6.57M 6.24% 1
2016
Q3 		$5.54M Buy
266,200
+3,800
+1% +$94.2K 5.97% 1
2016
Q2 		$7.06M Buy
262,400
+400
+0.2% +$11K 7.78% 1
2016
Q1 		$7.1M Hold
262,000
– – 7.82% 1
2015
Q4 		$7.61M Hold
262,000
– – 7.8% 1
2015
Q3 		$7.11M Hold
262,000
– – 7.52% 1
2015
Q2 		$7.17M Sell
262,000
-1,800
-0.7% -$50.6K 6.81% 1
2015
Q1 		$7.04M Buy
263,800
+800
+0.3% +$18.4K 6.26% 1
2014
Q4 		$5.57M Buy
263,000
+9,000
+4% +$201K 5.02% 1
2014
Q3 		$6.05M Hold
254,000
– – 5.58% 1
2014
Q2 		$5.87M Sell
254,000
-50,800
-17% -$1.12M 5.18% 1
2014
Q1 		$10.5M Buy
304,800
+50,800
+20% +$1.08M 5.02% 1
2013
Q4 		$4.69M Buy
+254,000
New +$4.43M 4.55% 1

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Penbrook Management's NVO Position: Q1 2026 in Review

Penbrook Management reduced its Novo Nordisk (NVO) stake by 0.06% in Q1 2026, selling an estimated $9.48K and leaving 316,200 shares worth $11.6M. The position accounts for 8.8% of the portfolio, ranked #1.

Penbrook Management first reported a position in NVO in Q4 2013 and has held it in 46 quarters since. The position peaked at $44.6M in Q2 2024. 1,271 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Penbrook Management held 316,200 shares of Novo Nordisk worth $11.6M as of Q1 2026.
  • Penbrook Management sold 200 Novo Nordisk shares in Q1 2026, an estimated $9.48K.
  • Novo Nordisk made up 8.8% of Penbrook Management's portfolio in Q1 2026, its #1 holding.
  • Penbrook Management first reported a position in Novo Nordisk in Q4 2013 and has held it in 46 quarters since.
  • Penbrook Management's Novo Nordisk position peaked at $44.6M in Q2 2024.
  • 1,271 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Penbrook Management's 13F filing for Q1 2026, filed 21 Apr 2026.